The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. METHODS: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. RESULTS: At the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cholesterol levels. Patients were followed for a median of 31 months. At a prespecified interim analysis that included 1135 primary end-point events (71% of the projected total number), the independent data and safety monitoring board recommended termination of the trial for futility. As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, respectively; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P=0.52) and did not have a significant effect on any component of the primary end point or total mortality. The median C-reactive protein level was 0.2 mg per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons). CONCLUSIONS: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last factor probably also contributed to the rise in LDL cholesterol observed in the placebo group, in the on-treatment analysis in the alirocumab group, and in previous trials involving patients who had an acute coronary syndrome. 5,21”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, early generations of CETP inhibitors were either associated with off-target adverse effects with safety concerns, or had no significant or only modest LDL-C lowering and thus failed to demonstrate cardiovascular benefit, leading to a loss of enthusiasm in this drug class [[7], [8], [9], [10]].”
From Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Anacetrapib reduced major coronary events by 9% over a median of 4.1 years [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“More recently, the REVEAL study investigated anacetrapib in > 30 000 patients with atherosclerotic vascular disease and resulted in a lower incidence of MACE compared with placebo after 4 years, with no safety concerns [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events. 362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events.362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [85]
In the citing paper
“However, three out of four prospective studies with CETP inhibitors had to be terminated due to increased mortality in the treatment group or due to futility (Table 3).”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [107]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 1,004
Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 60
Self-citationImproving Assessment of Drug Safety Through Proteomics
Williams, S. A., Murthy, A. C., DeLisle, R. K., Hyde, C. L., Mälarstig, A., Ostroff, R. M., Weiss, S. J., Segal, M. R., & Ganz, P. (2017) · Circulation · doi:10.1161/circulationaha.117.028213 · Cited by 58
Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
Mytilinaiou, M. G., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00707 · Cited by 61
Revealing the effect of CETP inhibition in cardiovascular disease
Holmes, M. V., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.156 · Cited by 56
Behl, T., Kaur, I., Sehgal, A., Zengin, G., Brisc, C., Brisc, M. C., Munteanu, M. A., Nistor-Cseppento, C. D., & BUNGAU, S. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249505 · Cited by 61
Kühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 58
Role of HDL in Those with Diabetes
Santos‐Gallego, C. G., & Rosenson, R. S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0512-5 · Cited by 59
Vora, A. N., Wang, T. Y., Hellkamp, A. S., Thomas, L. E., Henry, T. D., Goyal, A., & Roe, M. T. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002312 · Cited by 56
microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application
Desgagné, V., Bouchard, L., & Guérin, R. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0575 · Cited by 57
Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs
Padró, T., Cubedo, J., Camino-López, S., Béjar, M. T., Ben‐Aicha, S., Mendieta, G., Escolá‐Gil, J. C., Escate, R., Gutiérrez, M., Casaní, L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.018 · Cited by 57
PET imaging of the neurovascular interface in cerebrovascular disease
Evans, N. R., Tarkin, J. M., Buscombe, J. R., Markus, H. S., Rudd, J. H. F., & Warburton, E. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.129 · Cited by 56
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 56
Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Weber, C., Badimón, L., Mach, F., & van der Vorst, E. P. C. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0814 · Cited by 57
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 58
Masana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 57
A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease
Zhao, Q., Wang, J., Miao, Z., Zhang, N. R., Hennessy, S., Small, D. S., & Rader, D. J. (2021) · eLife · doi:10.7554/elife.58361 · Cited by 57
Does Vascular Calcification Accelerate Inflammation?
Joshi, F. R., Rajani, N. K., Abt, M., Woodward, M., Bucerius, J. A., Mani, V., Tawakol, A. A., Kallend, D. G., Fayad, Z. A., & Rudd, J. H. F. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.050 · Cited by 56
Self-citationCETP (Cholesteryl Ester Transfer Protein) Concentration
Blauw, L. L., Li‐Gao, R., Noordam, R., de Mutsert, R., Trompet, S., Berbée, J. F. P., Wang, Y., van Klinken, J. B., Christen, T., van Heemst, D., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002034 · Cited by 54
Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation
Tall, A. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.004 · Cited by 56
High-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly
Li, Z., Lv, Y., Zhong, W.-F., Gao, X., Kraus, V. B., Zou, M., Zhang, X.-R., Li, F.-R., Yuan, J.-Q., Shi, X., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02511 · Cited by 55
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 54
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53
Self-citationAn Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 55
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein
Kon, V., Yang, H., & Fazio, S. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.05.009 · Cited by 56
Human genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 54
Duprez, D. A., Otvos, J. D., Tracy, R. P., Feingold, K. R., Greenland, P., Gross, M. D., Lima, J. A. C., Mackey, R. H., Neaton, J. D., Sanchez, O. A., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002295 · Cited by 53
High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
He, Y., Kothari, V. M., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310222 · Cited by 56
Taheri, H., Filion, K. B., Windle, S. B., Reynier, P., & Eisenberg, M. J. (2020) · Cardiology · doi:10.1159/000505365 · Cited by 54
HDL cholesterol concentration or HDL function: which matters?
Barter, P. J., & Rye, K. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx274 · Cited by 54
Self-citationHigh Density Lipoproteins and Diabetes
Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Cells · doi:10.3390/cells10040850 · Cited by 52
Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
Madaudo, C., Bono, G., Ortello, A., Astuti, G., Mingoia, G., Galassi, A. R., & Sucato, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090996 · Cited by 57
High-density lipoprotein subfractions: current views and clinical practice applications
Martin, S. S., Jones, S. R., & Toth, P. P. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.05.005 · Cited by 54
Low-Normal Thyroid Function and Novel Cardiometabolic Biomarkers
van Tienhoven‐Wind, L. J. N., & Dullaart, R. P. F. (2015) · Nutrients · doi:10.3390/nu7021352 · Cited by 54
High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
Ossoli, A., Pavanello, C., & Calabresi, L. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.223 · Cited by 52
Lymphocyte activation gene 3 and coronary artery disease
Golden, D., Kolmakova, A., Sura, S. R., Vella, A. T., Manichaikul, A. W., Wang, X., Bielinski, S. J., Taylor, K. D., Chen, Y. I., Rich, S. S., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88628 · Cited by 52
The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease
Rhee, E., Byrne, C. D., & Sung, K. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000315 · Cited by 52
Did we abandon probucol too soon?
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000199 · Cited by 53
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 55
Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
Masana, L., Plana, N., Andreychuk, N., & Ibarretxe, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106738 · Cited by 53
Charles‐Schoeman, C., Lee, Y. Y., Shahbazian, A., Gorn, A. H., FitzGerald, J. D., Ranganath, V. K., Taylor, M. B., Ragavendra, N., McMahon, M. A., Elashoff, D. A., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38118 · Cited by 51
HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity
Borja, M. S., Ng, K. F., Irwin, A. D., Hong, J., Wu, X., Isquith, D. A., Zhao, X.-Q., Prazen, B. J., Gildengorin, V. L., Oda, M. N., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m059865 · Cited by 51
Time to ditch HDL-C as a measure of HDL function?
Ronsein, G. E., & Heinecke, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000446 · Cited by 51
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 52
Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective
Parhofer, K. G. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.020 · Cited by 50
2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
Zeitouni, M., Sabouret, P. F., Kernéis, M., Silvain, J., Collet, J., Bruckert, É., & Montalescot, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa077 · Cited by 56
Chen, J., Li, Y., Zhang, Y., Wang, Y., Zhou, Y., Geng, T., Liu, G., Pan, A., & Liao, Y.-F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155817 · Cited by 52
Ishikawa, T., Ayaori, M., Uto‐Kondo, H., Nakajima, T., Mutoh, M., & Ikewaki, K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.028 · Cited by 52
Human genetics as a foundation for innovative drug development
Kamb, A., Harper, S., & Stefánsson, K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2732 · Cited by 49
Dávalos, A., & Fernandez-Hernando, C. F. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.02.005 · Cited by 52
High-Density Lipoprotein Functionality in Coronary Artery Disease
Kosmas, C. E., Christodoulidis, G., Cheng, J.-W., Lerakis, S., & Vittorio, T. J. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000231 · Cited by 49
High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management
Choi, H. Y., Hafiane, A., Schwertani, A. G., & Genest, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.012 · Cited by 51
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 52
Self-citationFuruhashi, M., Ogura, M., Matsumoto, M., Yuda, S., Muranaka, A., Kawamukai, M., Omori, A., Tanaka, M., Moniwa, N., Ohnishi, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00177-w · Cited by 55
Nissen, S. E., Pillai, S. G., Nicholls, S. J., Wolski, K., Riesmeyer, J. S., Weerakkody, G. J., Foster, W. M., McErlean, E. S., Li, L., Bhatnagar, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0569 · Cited by 50
Self-citationHigh-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk
Asztalos, B. F., Horvath, K. V., & Schaefer, E. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311117 · Cited by 50
Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study
Thomas, D. G., Wei, Y., & Tall, A. R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p120001000 · Cited by 53
Pharmacogenomics in the era of next generation sequencing – from byte to bedside
Russell, L. E., Zhou, Y., Almousa, A. A., Sodhi, J. K., Nwabufo, C. K., & Lauschke, V. M. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1909613 · Cited by 52
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects
Kawashiri, M., Hayashi, K., Konno, T., Fujino, N., Ino, H., & Yamagishi, M. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0391-5 · Cited by 48
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 54
Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes
Triolo, M., Annema, W., de Boer, J. F., Tietge, U. J. F., & Dullaart, R. P. F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12226 · Cited by 49
Talayero, B., Wang, L., Furtado, J. D., Carey, V. J., Bray, G. A., & Sacks, F. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m042333 · Cited by 50
Bell, J. A., Hamer, M., Richmond, R. C., Timpson, N. J., Carslake, D., & Smith, G. D. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002649 · Cited by 50
Plasma HDL cholesterol and risk of myocardial infarction – Authors' reply
Voight, B. F., & Kathiresan, S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)62150-3 · Cited by 49
Advances in the Understanding of Plaque Composition and Treatment Options
Tomey, M. I., Narula, J., & Kovacic, J. C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.042 · Cited by 49
Dyslipidemia management update
Chang, Y., & Robidoux, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.005 · Cited by 50
Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype
Pasterkamp, G., van der Laan, S. W., Haitjema, S., Asl, H. F., Siemelink, M. A., Bezemer, T., van Setten, J., Dichgans, M., Malik, R., Worrall, B. B., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306958 · Cited by 49
van de Woestijne, A. P., van der Graaf, Y., Liem, A. H., Cramer, M. J., Westerink, J., & Visseren, F. L. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.101 · Cited by 48
New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism
Miyosawa, K., Watanabe, Y., Murakami, K., Murakami, T., Shibata, H., Iwashita, M., Yamazaki, H., Yamazaki, K., Ohgiya, T., Shibuya, K., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00528.2014 · Cited by 47
Farràs, M., Castañer, O., Martín‐Peláez, S., Hernáez, Á., Schröder, H., Subirana, I., Muñoz‐Aguayo, D., Gaixas, S., de la Torre, R., Farré, M., et al. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500030 · Cited by 48
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 48
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 48
Niacin and HDL Cholesterol — Time to Face Facts
Lloyd‐Jones, D. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1406410 · Cited by 48
Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
Kettunen, J., Holmes, M. V., Allara, E., Anufrieva, O., Ohukainen, P., Oliver-Williams, C., Wang, Q., Tillin, T., Hughes, A. D., Kähönen, M., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000572 · Cited by 47
Elliott, P. S., Kharaty, S. S., & Phillips, C. M. (2022) · Nutrients · doi:10.3390/nu14245371 · Cited by 53
Zhuang, J., Peng, W., Li, H., Lu, Y., Wang, K., Fan, F., Li, S., & Xu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082509 · Cited by 47
Hovingh, G. K., Rader, D. J., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000161 · Cited by 51
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
Salazar, J. J., Olivar, L. C., Ramos, E., Chávez-Castillo, M., Rojas, J., & Bermúdez, V. (2015) · Cholesterol · doi:10.1155/2015/296417 · Cited by 50
Lipoprotein Metabolism and Inflammation in Patients With Psoriasis
Armstrong, E. J., & Krueger, J. G. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.060 · Cited by 47
Chalmers, A. D., Bursill, C. A., & Myerscough, M. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187674 · Cited by 45
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Structural and functional changes in HDL with low grade and chronic inflammation
O'Neill, F., Riwanto, M., Charakida, M., Colin, S., Manz, J., McLoughlin, E., Khan, T. A., Klein, N. J., Kay, C. W. M., Patel, K., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.058 · Cited by 47
Brunham, L. R., Lonn, E., & Mehta, S. R. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.017 · Cited by 54
The role of high-density lipoproteins in the regulation of angiogenesis
Tan, J. T. M., Ng, M., & Bursill, C. A. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv104 · Cited by 49
Ruiz-Núñez, B., Kuipers, R. S., Luxwolda, M. F., Graaf, D. J. D., Breeuwsma, B. B., Dijck-Brouwer, J., & Muskiet, F. A. J. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.11.004 · Cited by 47
Niiranen, T., & Vasan, R. S. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1176528 · Cited by 49
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Hua, N., Qin, C., Wu, F., Wang, A., Chen, J., & Zhang, Q. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.08.017 · Cited by 45
Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome
Rosenson, R. S., Brewer, H. B., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302805 · Cited by 45
Sharif, S., van der Graaf, Y., Nathoe, H. M., de Valk, H. W., Visseren, F. L. J., Westerink, J., & on behalf of the SMART Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0155 · Cited by 45
Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment
Harada, A., Toh, R., Murakami, K., Kiriyama, M., Yoshikawa, K., Miwa, K., Kubo, T., Irino, Y., Mori, K., Tanaka, N. K., et al. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.022913 · Cited by 46
The use of mechanistic evidence in drug approval
Aronson, J. K., Caze, A. L., Kelly, M. P., Parkkinen, V., & Williamson, J. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12960 · Cited by 50
Atherosclerosis imaging using PET: Insights and applications
Sriranjan, R., Tarkin, J. M., Evans, N. R., Le, E., Chowdhury, M. M., & Rudd, J. H. F. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14868 · Cited by 45
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis
Rodríguez, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00902-3 · Cited by 47
Sriranjan, R., Zhao, T. X., Tarkin, J. M., Hubsch, A., Helmy, J., Vamvaka, E., Jalaludeen, N., Bond, S. J., Hoole, S. P., Knott, P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062602 · Cited by 44
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
Chyu, K., & Shah, P. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00187 · Cited by 44
Self-citationPharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 45
Krishnan, S., Huang, J., Lee, H., Guerrero, A., Berglund, L., Anuurad, E., Lebrilla, C. B., & Zivkovic, A. M. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00730 · Cited by 44
The High-Density Lipoprotein Puzzle
Rosenson, R. S. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 44
Plasminogen promotes cholesterol efflux by the ABCA1 pathway
Pamir, N., Hutchins, P. M., Ronsein, G. E., Hao, W., Tang, C., Das, R., Vaisar, T., Plow, E. F., Schuster, V. H., Koschinsky, M. L., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92176 · Cited by 45
Metadata
- Authors
- Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Mundl, H., Nicholls, S. J., Shah, P. K., Tardif, J.-C., & Wright, R. S.
- Affiliations
- Denver VA Medical Center (US)
- Linköping University (SE)
- F. Hoffmann-La Roche AG (CH)
- Baylor College of Medicine (US)
- University of Zurich (CH)
- Oslo University Hospital (NO)
- St. Michael's Hospital (CA)
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-11-29
- Volume
- 367
- Issue
- 22
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118825330
- Cited by
- 2,022
- References
- 35
- Citations by year
- 2026: 66 · 2025: 82 · 2024: 81 · 2023: 89 · 2022: 103 · 2021: 128 · 2020: 109 · 2019: 141 · 2018: 164 · 2017: 195 · 2016: 222 · 2015: 244 · 2014: 191 · 2013: 190 · 2012: 7
- FWCI
- 206.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche
- CSL Behring
- Amarin Corporation
- Anthera
- Kowa Company
- Servier
- Esperion Therapeutics
- Genentech
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- dalcetrapib, cholesteryl ester transfer protein inhibition, HDL cholesterol, acute coronary syndrome, cardiovascular risk, futility, LDL cholesterol, C-reactive protein, systolic blood pressure, myocardial infarction, ischemic stroke, unstable angina, cardiovascular mortality, lipid-lowering therapy
- MeSH terms
- Aged, Amides, Anticholesteremic Agents, Apolipoproteins, Blood Pressure, C-Reactive Protein, Cardiovascular Diseases, Esters, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Sulfhydryl Compounds, Triglycerides, Biomarkers, Cholesterol Ester Transfer Proteins, Acute Coronary Syndrome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
